Weekly signal · RKLB · Industrials

Rocket Lab USA Inc. (RKLB) rebounds as weekly confirmation stays weak

A 27.5% one-week advance lifted the shares, but the weekly price path over 52 weeks still shows a negative 12-week return.

Rocket Lab USA Inc.
Latest82.83 USD
1W move27.5%
Volume0.8x
TrendInactive
Weekly stock-chart context for Rocket Lab USA with aerospace launch and satellite equipment imagery.

Market update

What happened

Rocket Lab USA Inc. (RKLB) closed at $82.83 in the latest weekly market data, up 27.5% for the week. The move left the stock with a 2.2% four-week gain in weekly context.

The setup remains mixed. The 12-week return is still -33.6%, the trend signal is inactive, and Market Dynamics showed pressure at -1.06 despite the sharp weekly rebound.

Continue your research

Explore RKLB across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

RKLB coverage

Evidence context